Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Huifeng Bio-Pharmaceutical Technology has entered into a five-year agreement with Sichuan Huafamei Enterprise, a division of Safic Alcan Group, to supply Diosmin in the European market.
Subscribe to our email newsletter
The supply agreement calls for minimum guaranteed quantities of Diosmin to be delivered by Huifeng to Safic over each of the five years of the contract, which is renewable for an additional five-year term with mutual consent of both parties.
The minimum quantity of Diosmin to be delivered in year one is 50 tons, increasing yearly to at least 500 tons in the last year of the contract.
Diosmin is a semisynthetic phlebotropic drug used in the treatment of venous diseases like chronic venous insufficiency and hemorrhoidal disease, in acute or chronic hemorrhoids or as an adjuvant therapy to hemorrhoidectomy, in order to reduce secondary bleeding.
Jing’An Wang, CEO of Huifeng, said: “We are pleased to enter into this new agreement with Safic Alcan. Safic Alcan is committed to developing its presence in the European pharmaceutical industry.”